Ampersand Capital Partners Mergers and Acquisitions Summary

Growth Capital Firm Profile

In the last 3 years, Ampersand Capital Partners has acquired 9 companies. It has also invested in 13 others.

Ampersand Capital Partners’ most common sectors for investment arelife science (50%) and medical products (21%) . The Firm’s most common investment types include growth capital (33%) and buyout (lbo, mbo, mbi) (28%). In total, Ampersand Capital Partners has invested in 24 US states and 9 different countries. Its largest (disclosed) acquisition occurred in 2013 when it acquired BioClinica for $123M.

In the last 3 years, Ampersand Capital Partners has exited 12 companies. The Firm’s most common exit type is trade sale (72%). Ampersand Capital Partners’ largest (disclosed) exit occurred in 2008 when it sold Talecris Biotherapeutics Holdings Corp for $3.1B.

Join Mergr to view Ampersand Capital Partners’ full profile and discover more large growth capital firm investors just like it.

M&A Summary

  • M&A Total Activity131
    • M&A Buy Activity78
    • M&A Sell Activity53
  • Total Sectors Invested 15
  • Total Countries Invested 9
  • M&A Buy/Sell Connections 60
  • M&A Advisors 1

Ampersand Capital Partners

55 William St., Ste. 240,
Wellesley, Massachusetts 02481
United States
(781) 239-0700
www.ampersandcapital.com
info@ampersandcapital.com

Ampersand Capital Partners is a middle-market private equity group that concentrates on growth equity investment opportunities in the healthcare sector. The Firm looks to invest $10 to $100 million in businesses with $10 to $100 million of revenue. Specific areas of interests within healthcare include lab products, specialty diagnostic equipment, pharmaceutical outsourcing, and specialty pharma. Ampersand generally prefers to be the first and sole institutional investor. Ampersand was formed in 1988 and is based in Wellesley, Massachusetts.


Investment Criteria

Sectors of Interest: Healthcare Services, Life Science, Medical Products, Test/Measurement Equipment

Target Transaction Types: Buyout (LBO, MBO, MBI), Growth Capital, Recapitalization, Secondary Buyout, Stake Purchase, Venture

Geographic Preferences: East US, Midwest US, South US, West US, Canada, United Kingdom, Western Europe, Eastern Europe, Nordic

Transaction Criteria Min Max
Target Revenue 10 100
Target EBITDA - -
Investment Size 10 100
Enterprise Value - -
values in millions of USD

M&A Summary

Buy vs Sell

Year ≤ '19 '20 '21 '22 '23 '24 T
Buy (5.0/yr) # 53 4 7 9 3 2 78
vol $141M $141M
Sell (2.6/yr) # 40 1 6 6 - - 53
vol $6.2B $531M $152M $6.9B
  131

Most Recent M&A

Company Date Value Type
Biologos LLC 2024-03-19 - Secondary Buyout
Montgomery, Illinois · www.biologos.com
Specac Ltd. 2024-03-13 - Secondary Buyout
Orpington, United Kingdom · www.specac.com
Julius Clinical Research B.V. 2023-11-28 - Recapitalization
Zeist, Netherlands · www.juliusclinical.com
ProtaGene GmbH 2023-11-20 - Growth Capital
Heilbronn, Germany · www.protagene.com
NanoImaging Services, Inc. 2023-06-12 - Growth Capital
San Diego, California · www.nanoimagingservices.com
Alcami Corp., Inc. 2022-11-08 - Secondary Sale
Wilmington, North Carolina · www.alcaminow.com
Genome Diagnostics B.V. 2022-10-03 152M EUR Trade Sale
Utrecht, Netherlands · www.gendx.com
iuvo BioScience LLC 2022-09-28 - Buyout (LBO, MBO, MBI)
Rush, New York · www.iuvobioscience.com
AcuraBio Pty Ltd. 2022-09-07 - Buyout (LBO, MBO, MBI)
Darra, Australia · www.acurabio.com
Flagship Biosciences, Inc. 2022-09-01 - Growth Capital
Broomfield, Colorado · www.flagshipbio.com
View All >>

Portfolio M&A

Company Acquired Add-On/Sale Date #
Biosynth Carbosynth Ltd. 2021-11-01 Benen Trading Ltd. 2023-04-20 2
St. Gallen, Switzerland · www.carbosynth.com Bray, United Kingdom
Biosynth Carbosynth Ltd. 2021-11-01 Fitzgerald Industries International, Inc. 2023-04-20 1
St. Gallen, Switzerland · www.carbosynth.com Acton, Massachusetts
Biosynth Carbosynth Ltd. 2021-11-01 vivitide LLC 2022-03-17 8
St. Gallen, Switzerland · www.carbosynth.com Gardner, Massachusetts · www.vivitide.com
Biosynth Carbosynth Ltd. 2021-11-01 EUCODIS Bioscience GmbH 2022-01-01 7
St. Gallen, Switzerland · www.carbosynth.com Vienna, Austria · www.eucodisbioscience.com
Tjoapack Netherlands B.V. 2020-04-21 Pharma Packaging Solutions 2021-10-21 1
Etten-Leur, Netherlands · www.tjoapack.com Clinton, Tennessee · www.pharmapackagingsolutions.com
Precision Coating Co. Inc. 2021-09-20 N2 Biomedical 2021-09-20 2
Hudson, Massachusetts · www.precisioncoating.com Bedford, Massachusetts · www.n2bio.com

M&A by Sector

Sector Current # Value All-time # Value
Life Science 17 (59%) - 39 (49%) 123M (87%)
Medical Products 3 (10%) - 16 (20%) 18M (13%)
Chemicals 2 (7%) - 4 (5%) -
Healthcare Services - - 3 (4%) -
Software - - 3 (4%) -
Consumer Products - - 2 (3%) -
Information Technology 1 (3%) - 2 (3%) -
Manufacturing 1 (3%) - 2 (3%) -
Test/Measurement Equipment 1 (3%) - 2 (3%) -
Business Services 1 (3%) - 1 (1%) -
Consumer Services - - 1 (1%) -
Distribution 1 (3%) - 1 (1%) -
Packaging 1 (3%) - 1 (1%) -
Semiconductors - - 1 (1%) -
Transportation 1 (3%) - 1 (1%) -
Total 29 - 79 $141M

Acquisitions By Geo

State/Country Current # Value All-time # Value
United States 17 (59%) - 65 (82%) 141M (100%)
  Massachusetts 2 (7%) - 15 (19%) -
  California 2 (7%) - 11 (14%) -
  New Jersey 2 (7%) - 7 (9%) 123M (87%)
  Missouri 1 (3%) - 4 (5%) 18M (13%)
  Minnesota 1 (3%) - 3 (4%) -
  Arizona 1 (3%) - 3 (4%) -
  North Carolina - - 3 (4%) -
  Indiana 1 (3%) - 2 (3%) -
  Colorado 1 (3%) - 2 (3%) -
  Virginia 1 (3%) - 1 (1%) -
  Vermont 1 (3%) - 1 (1%) -
  Pennsylvania 1 (3%) - 1 (1%) -
  New York 1 (3%) - 1 (1%) -
  New Hampshire 1 (3%) - 1 (1%) -
  Illinois 1 (3%) - 1 (1%) -
  Wisconsin - - 1 (1%) -
  Washington - - 1 (1%) -
  Rhode Island - - 1 (1%) -
  Ohio - - 1 (1%) -
  Michigan - - 1 (1%) -
  Maryland - - 1 (1%) -
  Louisiana - - 1 (1%) -
  Georgia - - 1 (1%) -
  Florida - - 1 (1%) -
Germany 3 (10%) - 3 (4%) -
Netherlands 2 (7%) - 3 (4%) -
United Kingdom 2 (7%) - 2 (3%) -
New Zealand 2 (7%) - 2 (3%) -
Australia 1 (3%) - 1 (1%) -
Sweden 1 (3%) - 1 (1%) -
Switzerland 1 (3%) - 1 (1%) -
Canada - - 1 (1%) -
  Quebec - - 1 (1%) -
Domestic 17 (59%) - 65 (82%) 141M (100%)
Cross-border 12 (41%) - 14 (18%) -
Total 29 - 79 $141M

Acquisitions by Deal Type

Type Current # Value All-time # Value
Growth Capital 13 (45%) - 26 (33%) -
Buyout (LBO, MBO, MBI) 5 (17%) - 22 (28%) -
Venture 1 (3%) - 11 (14%) 18M (13%)
Recapitalization 4 (14%) - 6 (8%) -
Secondary Buyout 3 (10%) - 5 (6%) -
Divestiture - - 4 (5%) -
Stake Purchase 2 (7%) - 2 (3%) -
Going Private - - 1 (1%) 123M (87%)
PIPE 1 (3%) - 1 (1%) -
Special Situations/Distressed - - 1 (1%) -
Total 29 - 79 $141M

Exits by Deal Type

Type Total # Value
Trade Sale - Public Company 20 (38%) 6.8B (98%)
Trade Sale 19 (36%) 127M (2%)
Secondary Sale 5 (9%) -
Merger 4 (8%) -
IPO 3 (6%) -
Recapitalization 1 (2%) -
Unknown 1 (2%) -
Total 53 $6.9B

Top M&A Advisors

Legal Deals
Edwards Wildman Palmer LLP
 1

Deal Values

buy # Total
$100M to $1B 1 $123M
< $100M 1 $18M
TOTAL $141M
Largest BioClinica, Inc.
$123M (2013-03-13)
sell # Total
> $1B 2 $4.8B
$100M to $1B 9 $2.0B
< $100M 2 $76M
TOTAL $6.9B
Largest Talecris Biotherapeutics Holdings Corp
$3.1B (2008-08-12)

M&A Connections

Deals
Acquired from
Investor(s)
6%
5 (6%)
Strategic(s)
5%
4 (5%)
Exited to
Investor(s)
11%
6 (11%)
Strategic(s)
77%
41 (77%)

Investor Summary

Investor Type

Growth Capital Firm

Size

Large

PE Assets

2.0B USD

Established

1988

Specialist/Generalist

Specialist

Leadership

Richard Charpie

Founder & Managing Partner

David Anderson

General Partner

David Parker

General Partner

Eric B.Lev

General Partner

Herbert Hooper

Managing Partner

FAQ

When was Ampersand Capital Partners founded?

Ampersand Capital Partners was founded in 1988.

What type of investor is Ampersand Capital Partners?

Ampersand Capital Partners is a growth capital firm.

Where is Ampersand Capital Partners headquartered?

Ampersand Capital Partners is headquartered in Wellesley, Massachusetts.

How much capital does Ampersand Capital Partners have under management?

Ampersand Capital Partners has 2.0B USD under management.

 Subscribe to unlock this and 206,758
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More
1 Week Free Trial Learn More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB

Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 199K M&A Transactions
  • 202K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 80K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.

Mergr

Product

Company

Legal